title: Long-term culture of autologous transplanted bone marrow for acute myeloid leukaemia: evidence for an in vitro haemopoietic defect and lack of correlation with the speed of engraftment.
abstract: Haematological recovery after autologous bone marrow transplantation (BMT) for acute myeloid leukaemia (AML) is often delayed and available laboratory assays cannot accurately predict speed of engraftment. By using the long-term bone marrow culture (LTBMC) method, we attempted to define the haemopoietic defect underlying this slow engraftment, and assessed the usefulness of LTBMC in predicting engraftment. Cryopreserved bone marrow (BM) harvested from three different groups (AML autografts, n = 18; autografts for non-leukaemic diseases, n = 23; normal donors. n = 10) were cultured and their growth was compared and correlated with the speed of engraftment. In the AML autografts, non-adherent and adherent progenitor production was significantly reduced compared with normal BM during the whole culture period (P < 0.01). None of the LTBMC parameters was found to correlate with engraftment after autologous BMT. The non-leukaemic autografts showed progenitor production intermediate between normal and AML autografts. Their progenitor content at the end of the culture period (reflecting the stem cell pool) was not statistically different from normal BM. In this group, most of the progenitor cell contents, during LTBMC correlated with neutrophil (rs = -0.618 to -0.879, P < 0.01) and platelet (rs = -0.479 to -0.707, P < 0.02) recovery. The conclusion drawn from these results is that AML autografts are defective in their ability to sustain in vitro haemopoiesis, but this in vivo defect does not correlate with the slow haemopoietic recovery after autologous BMT. In contrast, LTBMC of autografts for non-leukaemic diseases, whose defect affects the stem cell pool to a lesser extent than BM in AML correlates with the speed of engraftment.
authors.affiliation: Department of Haematology, Catholic University of Louvain, Brussels, Belgium.
authors.forename: N
authors.initials: N
authors.lastname: Straetmans
authors.forename: D D
authors.initials: DD
authors.lastname: Ma
authors.forename: P
authors.initials: P
authors.lastname: Herman
authors.forename: A
authors.initials: A
authors.lastname: Zenebergh
authors.forename: A
authors.initials: A
authors.lastname: Chang
authors.forename: V
authors.initials: V
authors.lastname: Deneys
authors.forename: M
authors.initials: M
authors.lastname: De Bruyère
authors.forename: A
authors.initials: A
authors.lastname: Ferrant
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D001707:Biopsy, Needle; D001853:Bone Marrow / Q000473:pathology*; D016026:Bone Marrow Transplantation; D003114:Colony-Forming Units Assay; D006085:Graft Survival; D006098:Granulocytes; D006410:Hematopoiesis; D006801:Humans; D007951:Leukemia, Myeloid / Q000473:pathology* / Q000628:therapy; D008264:Macrophages; D008875:Middle Aged; D014182:Transplantation, Autologous